$EXPO

Corrigan Catherine sold $235K of EXPO

Corrigan Catherine (President & CEO) sold 4,119 shares of EXPONENT INC (EXPO) at $57.13 ($0.24M total) across 2 trades on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Corrigan Catherine
Published Jun 17, 2026, 9:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EXPO
Neutral
high confidence
Mentioned
$EXPO
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EXPONeutralLow
01

Why it matters

This is a disclosed insider sale by the CEO under a pre-arranged 10b5-1 plan; it is more relevant for sentiment monitoring than for fundamental repricing.

02

Market read

Traders may note the disclosed insider selling, but the 10b5-1 structure suggests limited incremental information versus discretionary sales.

03

What to watch

The article provides only the sale details; it does not include any offsetting buys, changes in guidance, or operational catalysts that would better explain directionality.

Relevance 3/10Novelty 6/10Timing: Filed 2026-06-17; sale executed 2026-06-15.

Background

SEC Form 4 reports an officer/director insider transaction for Exponent Inc (EXPO).

Company-level read

Ticker impact

$EXPONeutralHigh confidence
Context

Exponent Inc CEO Corrigan Catherine sold $235.3K of EXPO shares via a Rule 10b5-1 plan on 2026-06-15 at $57.1263.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider sale by the CEO, but it explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider sales can coincide with valuation or liquidity needs; traders may still treat it as a mild caution flag.

Key entities

  • Exponent Inc

    Subject of the Form 4 insider transaction; CEO Corrigan Catherine sold shares on 2026-06-15.

  • Corrigan Catherine

    President & CEO; executed open-market sale totaling $235,303.23 under a Rule 10b5-1 plan.

Related articles

$EXPOMedAI 8/10

Exponent (EXPO) Q2 2026 Earnings Call Transcript

Exponent, Inc. (EXPO) reported Q2 2026 net revenues of $148.9 million, up 12% from $132.9 million a year earlier, and net income of $29.4 million, up 11%. Diluted EPS was $0.60. Management raised FY 2026 revenue guidance to 9% to 10% growth and EBITDA margin to 27.8% to 28.1%, and authorized an additional $50 million for share repurchases.

$EXPOMedAI 8/10

Exponent Q2 Earnings Call Highlights

Exponent (NASDAQ:EXPO) reported Q2 EBITDA up 16% to $42.7 million, with EBITDA margin at 28.7% of net revenue versus 27.8% a year earlier. Billable hours rose 8% to about 390,000 and utilization increased to 74%. The company repurchased $67.4 million of stock and paid $14.8 million in dividends. It raised 2026 outlook for net revenue growth of 9% to 10%.